Next Article in Journal
First Observations of Cirrus Clouds Using the UZ Mie Lidar over uMhlathuze City, South Africa
Next Article in Special Issue
Dependence of Electric Pulse Mediated Growth Factor Release on the Platelet Rich Plasma Separation Method
Previous Article in Journal
Assessment of Heavy Metal and Oil-Contaminated Silty Sand Treatment by Electrical Resistance Heating Method
Previous Article in Special Issue
Four Channel 6.5 kV, 65 A, 100 ns–100 µs Generator with Advanced Control of Pulse and Burst Protocols for Biomedical and Biotechnological Applications
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

The Granger Causal Effects of Canady Helios Cold Plasma on the Inhibition of Breast Cancer Cell Proliferation

Jerome Canady Research Institute for Advanced Biological and Technological Sciences, Takoma Park, MD 20912, USA
School of Medicine, University of Massachusetts, Worcester, MA 01605, USA
Department of Mechanical and Aerospace Engineering, The George Washington University, Washington, DC 20052, USA
Department of Surgery, Holy Cross Hospital, Silver Spring, MD 20910, USA
Author to whom correspondence should be addressed.
Appl. Sci. 2022, 12(9), 4622;
Submission received: 23 March 2022 / Revised: 27 April 2022 / Accepted: 2 May 2022 / Published: 5 May 2022
(This article belongs to the Special Issue Biomedical Applications of Pulsed Power and Plasmas)


Cold atmospheric plasma (CAP) has become a promising tool for modern medicine. With its recent applications in oncology, regenerative medicine, and immunotherapy, CAP can be used for a myriad of different clinical treatments. When using CAP specifically for the treatment of tumors, it is known to elicit an oxidative response within malignant cancer cells, inducing cell cycle arrest and apoptosis. In this study, data of intracellular reactive oxygen species (ROS), caspase activity, Ki-67 expression, and cell cycle activity in the G1 phase were acquired to determine the causal relationships these intermediates have with cell proliferation and death after Canady Helios Cold Plasma (CHCP) treatment. The data were derived from four different subtypes of breast cancer cell lines: BT-474, MCF-7, MDA-MB-231, and SK-BR-3. Data transformation techniques were conducted on the time-series data for the input into the causal model code. The models were created on the basis of Granger causality principles. Our results demonstrated that there was a Granger causal relationship among all potentially causal variables (ROS, caspase, Ki-67, and G1 activity) and cell proliferation after 5 min CHCP treatment; however, not all variables were causal for the 3 min models. This same pattern did not exist for cell death models, which tested all potentially causal variables (ROS, Ki-67, and G1 activity) vs. caspase activity. All models were validated through a variety of statistical tests and forecasting accuracy metrics. A pseudo data set with defined causal links was also created to test R’s ability in picking up known causal relationships. These models, while nonexhaustive, elucidated the effects cold plasma has on cell activity regulators. Research in causal modeling is needed to help verify the exact mechanism of cold plasma for the ultimate optimization of its application in the treatment of cancers.

1. Introduction

Breast cancer is a result of random mutations that allow breast cells to grow and proliferate without the tight restrictions imposed on them during the cell cycle [1]. These mutations affect several of the cells’ homeostatic parameters, including their cellular metabolism, proliferation rate, and the defenses they establish to circumvent cell cycle arrest or controlled death [1]. Given this, breast cancers can be categorized into four groups based on genetic information: luminal A, luminal B, HER2-positive, and triple-negative. These four types, as seen in Table 1, are classified based on whether or not the cancer cells possess (1) the human epidermal growth factor receptor 2 (HER2) protein, a type of transmembrane receptor tyrosine kinase and (2) hormone receptors, including estrogen receptors (ER) and/or progesterone receptors (PR), within the cell membrane [1]. Luminal A breast cancers, such as the MCF-7 cell line, are HER2-negative and hormone receptor-positive [2]. These cancers tend to grow slowly due to low levels of Ki-67, a tumor proliferative marker that helps control the pace of the cell growth by preventing the aggregation of mitotic chromosomes [2,3]. Luminal B breast cancers, such as the BT-474 cell line, are hormone receptor-positive, and either HER2-negative or -positive, with high levels of Ki-67 [2]. HER2-positive breast cancer, as the name suggests, is HER2-positive and hormone receptor-negative [4]. SK-BR-3 falls under HER-2 classification. Triple-negative breast cancers, such as MDA-MB-231, do not express any of the three main receptors, making it more aggressive and difficult to treat than the other breast cancers [5].
Receptor status determines the initial prognosis and the ensuing treatment of the cancer since certain subtypes do not respond to targeted hormone therapies. Many standard systemic and localized cancer treatments are unable to precisely kill microscopic disease around the tumor site and often affect healthy adjacent tissue [6,7]. In the case of chemotherapy and endocrine therapy, these treatments also worsen the quality of life to a greater extent and for a longer period of time [8]. However, some modern treatments not only work to actively kill cancer cells but also mitigate the chance of recurrence after tumor resection without worsening the patient’s quality of life [9,10]. One such treatment is through the use of cold atmospheric plasma (CAP).
CAP is a room temperature ionized gas, generating a composite of charged particles, photons, and an electric field [11]. CAP also gives rise to a cellular environment rich in reactive oxygen species (ROS) and reactive nitrogen species (RNS). Major CAP-generated ROS include ozone (O3), singlet oxygen (1O2), superoxide anion (O2˙−), and hydroxyl radical (˙OH). The major RNS generated include nitric oxide (˙NO) and nitric dioxide (˙NO2) [12]. These reactive species yield peroxynitrite (ONOO-), hydroxide (H2O2), and nitrite (NO2) when in contact with bodily fluid or a cell culture medium [13]. Excess cellular levels of these species can lead to the activation of apoptosis due to the damage they cause to mRNA [14], vital proteins, nucleic acids, lipids, membranes, and organelles [15]. During apoptosis signaling, caspase precursors undergo rapid proteolytic processing and activation [16]. Activated caspases function to hydrolyze key enzymes and degrade cellular proteins necessary for the survival and growth of the cell, resulting in cell death [16]. Additionally, a decrease in mitotic cell division and a reduction of Ki-67 expression in tumor cells could indicate CAP-induced cell death post treatment. Ki-67 is a nuclear protein that is expressed in actively proliferating cells during all phases of the cell cycle [17]. CAP prompts a decrease in Ki-67 as it is known to selectively induce apoptosis and cell cycle interruption [18]. Cell cycle interruption caused by CAP oxidizes histone mRNA and activates cell cycle checkpoints that halt the cells from undergoing further development [14]. The G1 phase in the cell cycle is the time in which cells physically grow and their organelles develop [19]. When this growth process is interrupted by CAP, cancer cells can no longer proliferate at an uncontrollable rate.
While studies show strong temporal correlations among CAP treatment, a decrease in cell proliferation, and an increase in cell death, several different theories of the CAP’s mechanism of action exist due to the complex microprocesses involved in its ability to trigger cell cycle arrest and apoptosis. Our approach aims to bridge the gap in knowledge regarding these CAP-induced outcomes. Although the literature has implied correlations among cell signaling intermediates, cell proliferation, and cell death, the three have not been combined in a comprehensive causal model thus far. A causal model is one that examines the relationships between potential causes and potential effects.
Granger causality is a way to investigate causality between two variables in a time series, a sequence of data points that occurs in successive order over a period of time [20]. Granger causality tests whether a variable, the potential “cause”, is helpful for forecasting, or predicting, the behavior of another variable, the potential “effect”. By using empirical data sets to find patterns of correlation, the formulated vector autoregressive (VAR) model assumes the data-generating processes in any time series are independent variables. In a VAR model, each variable is regressed on all variables, including itself, at previous time points. Regression is a statistical method that attempts to determine the strength and character of the relationship between variables, revealing the temporal dynamics of a system of related parameters across time. A VAR model itself is made up of a system of equations that represents the relationships between the variables. The data sets are analyzed to see if they are correlated, verifying the usefulness of one variable to forecast another [20]. Therefore, according to Granger causality, if X “Granger-causes” Y, then past values of X should contain information that helps predict Y above and beyond the information contained in past values of Y alone [21].
In this study, Granger modeling was used to compare the individual effects of intracellular ROS, caspase activity (CA), Ki-67 expression, and G1 phase activity on cell proliferation and cell death after treatment with Canady Helios Cold PlasmaTM (CHCP). CHCP was developed at the Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS) (U.S. Patent No. 9,999,462 B2 June 2018 [22]), and previous studies have demonstrated its anticancer effect on a variety of solid tumor cell lines including breast cancers [23,24]. The primary objective of this study is to identify causal versus correlational links of intracellular oxidative stress, CA, Ki-67 expression, and cell cycle to the death of breast cancer cells. The rationale for developing a computational causal model is that it can help answer questions on what variables need to be prioritized for future in vivo mammalian studies.

2. Materials and Methods

2.1. Data Acquisition

The data used to construct the models were acquired from the experiments performed at the Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS) in Takoma Park, MD, USA. The CAP generation device used in this study, CHCP, has been described in our previous studies [25]. It is comprised of a high-frequency electorsurgical generator and a conversion unit. The conversion unit utilizes a high voltage transformer connected to the output from the electrosurgical generator and upconverts voltage up to 4 kV while downconverting frequency and power to less than 300 kHz and 40 W, respectively. The main reactive oxygen and nitrogen species generated by CHCP were OH (A2Σ+-X2Π+) at 309 nm; N2 (C3Πu-B3Πg) second positive system (SPS) at 337 and 357 nm; N2+ (B2Σu+-X2Σg+) first negative system (FNS) at 391 and 427 nm; He at 667 nm; and OI at 777 nm as reported in the spectrum in [23]. Human breast ductal carcinoma BT-474 and breast adenocarcinoma SK-BR-3 were purchased from ATCC (Manassas, VA, USA). Human adenocarcinoma cell lines MCF-7 and MDA-MB-231 were generously donated by Professor Yasmine Kanaan’s laboratory at Howard University. Cells were cultured in ATCC-recommended media supplemented with 10% fetal bovine serum and 1% Pen Strep (Thermo Fisher Scientific, Waltham, MA, USA) in a 37 °C and 5% CO2 humidified incubator (Thermo Fisher Scientific, Waltham, MA, USA). When cells reached approximately 80% confluence, cells were seeded at a concentration of 105 cells/well into 12-well plates (USA Scientific, Ocala, FL, USA). Helium flow was set to a constant 3 lpm, and power was set to 80 p (equivalent to 15.7 W) or 120 p (equivalent to 28.7 W). Cells were treated directly by CHCP 24 h after being seeded, and the plasma scalpel was placed 1.5 cm away from the surface of the cell media. The data metrics, including intracellular ROS, caspase activity (CA), Ki-67 expression, G1 activity, and confluence for each cell line were acquired up to 48 h after treating all cells with CHCP for 3 and 5 min at 120 p except for the SK-BR-3 cell line, which was treated at 80 p for Ki-67 models.
Data of intracellular ROS, CA, cell cycle, and proliferation were collected by IncuCyte® (Sartorius, Göttingen, Germany). The inputted data needed to be time-series dependent and composed of at least 48 data time points that were of the same hourly time scale. Therefore, experimental data generated by IncuCyte® Live-Cell Analysis System (Sartorius, Göttingen, Germany) were proper and convenient in that IncuCyte® (Sartorius, Göttingen, Germany) enables imaging and continuous quantification of cell behavior over time. Protocols and data for CA, cell cycle, and confluence for the 4 breast cancer cell lines have been reported in our previous work [14]. The experimental protocol for intracellular ROS was performed as follows: prior to CHCP treatment, cells were stained for intracellular ROS with CM-H2DCFDA (ThermoFisher Scientific, Waltham, MA, USA) at appropriate concentrations according to manufacturer’s instructions, incubated under standard conditions of 37 °C and 5% CO2 for 30 min, replenished with fresh warm media, and then incubated under the same conditions again for 30 min for recovery. After CHCP treatment at 120 p (equivalent to 28.7 W) for 3 and 5 min, intracellular ROS activity for all cell lines was monitored and quantified in the IncuCyte® in an incubator for 48 h under standard conditions. CHCP-generated H2O2 and NO2 concentrations were measured in PBS by colorimetric kits (Sigma-Aldrich, St. Louis, MO, USA and Promega, Madison, WI, USA). Corresponding concentrations of H2O2 and NO2 were added to the cells for intracellular ROS measurement as positive controls.
Ki-67 data, also published in our previous work [14], was collected using confocal microscope imaging at 6, 24, and 48 h post CHCP treatment. The number of Ki-67-positive cells was counted for each cell line after CHCP treatment. Ki-67 data required interpolation due to sparse data. Using the dplyr package, a data cleaning tool in R, interpolation was used to fill in gaps in the time-series data in order to have consistent hourly time intervals for each variable.
Each data set was normalized to no treatment (control) and averaged. The data were combined into standardized headers for data preprocessing. Cell proliferation, represented by confluence data, was defined as one “effect” variable, and cell death, represented by CA data, was the secondary “effect” variable.

2.2. Construction of Model

The Granger causal statistical analysis methodology was used in model formation. F-statistics and resulting p-values were generated through the vars package embedded within R software (Version 1.4.1717). The VAR() function created multivariate time-series equations where the endogenous variables in the system are functions of the lagged values of all endogenous variables [26]. Principles of mathematical regression were used within R’s functions to generate the multivariate equations. Regression is defined as a system of statistical analysis that estimates the strength of correlation and the directionality of data [26]. The outputted regression equations of the model represent the relationships each variable has with cell proliferation or cell death. A lag order of 1 was determined using the VARselect() function, which outputted the optimal lag based on different information criterion (IC). The Akaike Information Criterion (AIC) tests how well the model fits the data set without overfitting it and therefore was used in determining the IC score.
Regression analysis alone cannot be used to reveal causality because it only establishes the impact of the predictive variables on the dependent variables tested [26]. In simple regression, the equations merely reflect that “x” has a relationship with “y”. To infer causality, that relationship must reflect that “x” causes “y”. Therefore, after a VAR equation was obtained for each potentially causal variable (intracellular ROS, CA, Ki-67+ count, and G1 activity) vs. cell proliferation, the equation and its associated parameters were inputted into the causality() function. ROS, Ki-67+ count, and G1 activity were subsequently used to assess cell death causality, with CA used as the “y” term. The causality function then outputted p-values that represented whether or not each relationship displayed statistically significant causality. Tables were generated to organize the p-values of each model for later analysis. Models were created from data collected after 3 and 5 min of CHCP treatment.

3. Results

Breast cancer cell lines of four different subtypes were treated by CHCP for 3 or 5 min. Following the treatment, a set of data including intracellular ROS, CA, Ki-67+ count, G1 activity, and confluence was obtained every hour for 48 h. Intracellular ROS as an oxidative stress maker was monitored, and the data are shown in Figure 1. All data plotted were subtracted by breast cancer cells stained with the fluorescent probe (CM-H2DCFDA) but without CHCP treatment. CHCP-generated H2O2 and NO2 concentrations were measured in PBS by colorimetric, and corresponding concentrations of H2O2 and NO2 were added to the cells for intracellular ROS measurement as positive controls. Compared to no treatment, treatment with CHCP 120 p at both 3 and 5 min caused a significant increase in ROS levels in all breast cancer subtypes. Fluorescent intensity (Y-axis) was brought to the same scale for each cell line treated by CHCP for 3 and 5 min for easy comparison. Treatment with chemicals alone (H2O2 or NO2 or in combination) also induced increased ROS levels in all four subtypes, especially at higher concentrations, but the increased intensity was much lower compared to CHCP-induced ROS.
The VAR() function in R was used in conjunction with the causality() function to generate several models using the inputted data. Cell proliferation data, represented by confluence data, were defined as one “effect” variable, and cell death, represented by CA data, was the secondary “effect” variable. Table 2 and Table 3 display the p-values and coefficients of the cell proliferation models for the 3 and 5 min CHCP treatment times, respectively, and Table 4 and Table 5 display the outputs of the 3 and 5 min cell death models, respectively. Significant models yielded p-values under 0.05, the chosen critical value, after being treated with CHCP for a set amount of time. The absolute values of the coefficients of regression were also outputted from the VAR() function. These coefficients indicate the weight of causality. Only the coefficients of significant models can be accurately compared.
For the 3 min CHCP treatment models with cell proliferation set as the effect variable, different variables displayed causality depending on the cell line studied. The significant causal variables and their associated coefficients can be seen in Table 2. The models that had significant Granger causal relationships were denoted as * (p < 0.05). The Ki-67 model for SK-BR-3 was formulated based on data acquired after 80 p CAP treatment as opposed to 120 p because CHCP at 120 p eliminated all SK-BR-3 cells, making it technically impossible for confocal microscopy to image any cells. This condition is present within all of SK-BR-3’s Ki-67 models. The absolute value of the coefficients of regression represents the weight of causality. CA was the only variable that lacked causality for the BT-474 cell line, whereas it was the only one which demonstrated causality for the MDA-MB-231 cell line. The intracellular ROS level did not display causality for cell proliferation in neither the MCF-7 nor the MDA-MB-231 cell lines but was significant in BT-474 and SK-BR-3. Based on the weighted coefficients, CA showed the greatest causality for the MCF-7 and MDA-MB-231 cell lines, while Ki-67 showed the greatest causality for the BT-474 and SK-BR-3 cell lines. Cell cycle activity data could not be collected for the SK-BR-3 cell line using the IncuCyte, and hence no models could be formed to test causality.
The same data analysis was conducted for cells treated with CHCP for 5 min. For the 5 min treatment, all variables showed causality (see Table 3) when proliferation was set as the effect variable. Ki-67 showed the greatest causality for all cell lines, except MCF-7, after 5 min of CAP treatment. ROS models had the lowest absolute valued coefficients on average.
Models were also created with cell death, represented by the CA variable, as the effect. These models are displayed in Table 4, for 3 min CHCP treatment. Cell proliferation was omitted as a causal variable because a lack of cell proliferation does not have any definite causal linkage to cell death. All inputted variables were causal for the MCF-7 and SK-BR-3, while none were causal for MDA-MB-231. Only Ki-67 and G1 activity showed causality for the BT-474 models. Ki-67 had the greatest causal relationship to CA across all cell lines.
Shown in Table 5, the same causality testing was then done for cell death using data from cells that underwent CHCP treatment for 5 min. When comparing the 3 min and 5 min cell death models, it was seen that the G1 variable for BT-474 and the ROS and Ki-67 variables for MCF-7 did not have significant causal link after 5 min CHCP treatment. However, the same variables were considered significantly causal for the 3 min models. This was inconsistent with the cell proliferation models, where all 5 min models were statistically significant, including those that had p-values > 0.05 in the 3 min models.
The standard errors for the ROS, CA, Ki-67, and G1 models are presented in Table 6. The error of the models varied greatly among cell types. The standard of error for each model was computed from the causality() function in R, alongside the estimated p-values. The SK-BR-3 ROS models had the smallest error on average, while the MCF-7 caspase models had the largest.

3.1. Model Validation

To validate the models, the vars, tseries, and forecast packages in R were utilized in order to conduct diagnostic statistical testing on time-series models that had demonstrated Granger causality (p-value < 0.05). Autocorrelation was utilized to determine if there was a similarity present between observations as a function of the time lag between them [21]. Autocorrection existed across all cell lines, suggesting that previous observations of the time series have an influence on the current state, whether that be of ROS, CA, and Ki-67 expression or G1 activity.
Another metric to consider is heteroscedasticity or the volatility of the changing variance in data [27]. Heteroscedasticity is present if the dependent variable changes significantly from the beginning to the end of the time series [21]. Heteroscedastic behavior was demonstrated across all variables for each significant model. This indicates that there were large ranges between the largest and smallest observed values of the data sets.
The last metric, stability, tests for the presence of structural breaks, which is important because model accuracy declines when structural breaks go undetected [28]. CUSUM processes, which contained cumulative sums of standardized ordinary least squares (OLS) residuals, were computed, providing evidence as to whether or not a structural change occurred. In a time-series analysis, structural changes represent shocks impacting the evolution with time of the data generating process [28]. In order to fail the stability tests, the data would need to fall outside of the red boundaries in the generated plots, which were determined from the stability() function in R. An example plot of the stability test for the 3 min treatment MDA-MB-231 Ki-67 model is shown in Figure 2. The data exhibit no structural breaks as no point exceeds the red boundaries. After calculating and plotting the empirical fluctuation process for all significant models, each variable was seen to pass this metric.

3.2. Model Verification

Another large portion of validation for this project was the software validation portion. We wanted to test R’s ability in picking up on Granger causal relationships if data that we knew had causal relationships were inputted. In order to input pseudo data that had distinct causal links, four variables were generated in MATLAB [Version R2022a]—Y, Z, N, and P. In order to generate these variables, Y was first defined as the first 48 values of a sin() function. An upward trend was added by increasing each Y data point by a random value between 0.01 and 1.5. Then, a random component was added by adding a random number within −1.5 and 1.5 to each Y value. Next, the variables Z, N, and P were made with respect to Y. The variables Z, N, and P are as follows: Z = 2Y3 − Y2 + 5Y, N = 33Y, and P = 3Y + 2. Once the test data set was completed, it was subsequently run through the Granger causality code. All combinations of Y, Z, N, and P models were tried, and all models resulted in a p-value of 2.2 × 10−16, which is how R outputs p-values less than 0.0001. In addition to running the test data set through the Granger causal code, the same statistical VAR tests done for ROS, CA, Ki-67, and G1 data were also completed. All tests were passed.

4. Discussion

The intracellular levels of ROS, CA, Ki-67+ count, and cell cycle activity can independently help indicate whether cell proliferation or cell death is occurring for cells treated with CHCP. This study thus aimed to pinpoint which variables affect cell proliferation and cell death in a Granger causal manner. The Granger causal model is a prediction-based statistical concept of causality in which empirical data is used to find patterns of correlation. Granger causality is also known as a “bottom-up” procedure because it assumes two time-series variables are independent of one another. The variables are then subsequently analyzed for correlation. This is different from “top-down” procedures which initially assume a link between the time series variables [21].
Prior to model generation, it was hypothesized that ROS would act as the main proxy of causality due to the widespread effects of oxidation on the cell cycle. Intracellular ROS measurements indicated that after CHCP treatment, all breast cancer cell lines underwent oxidative stress, which gradually increased with post-treatment incubation time. For both cell proliferation and cell death, while not all ROS models indicated Granger causality, as seen by p-values > 0.05, this does not mean that ROS did not heavily influence upstream actions. The effects of oxidative species may have affected other cellular processes in a more direct manner. For the 3 min CHCP treatment cell proliferation models, it was seen that only BT-474 and SK-BR-3 displayed ROS Granger causality. Both of these cell lines are HER2+, with ER/PR receptors present in BT-474 cancer cells and no ER/PR receptors present in SK-BR-3. The cell lines that did not display ROS causality, MCF-7 and MDA-MB-231, are both HER2. Ligand-mediated stimulation of HER2 receptors causes auto-phosphorylation of key tyrosine residues that serve as docking sites for downstream signaling cascades that regulate normal cell function by promoting growth and survival. However, when disrupted, HER2 can spur on the growth of cancer [4]. Given this, HER2+ cell lines are more likely to respond to treatment that directly targets the HER2 protein itself. The results of this study may suggest that CHCP does directly affect the HER2 transmembrane protein in a way that would signal Granger causality.
It was also seen that the coefficient of regression for the SK-BR-3 3 min ROS model was significantly smaller than that of the BT-474 ROS model. This may be due to the fact that SK-BR-3 has no hormone receptor, while BT-474 is both ER+ and PR+ [1]. Based on the results, CAP-induced ROS may have a greater impact on cells with a greater number of different receptors. A lack of hormone receptors may cause cells to have a certain degree of tolerance to different oncological therapies, including CAP.
CA showed consistent causality for all of the 3 min cell proliferation models, except that of the BT-474 cell line. This is because BT-474 treated by CHCP at 120 p for 3 min did not induce activation of caspase (data shown in [14]). When treated for 5 min, CA of all four cell lines showed causality towards proliferation, but BT-474’s coefficient being the smallest also confirmed lower CHCP-induced caspase activation in this cell line.
It was also found that the Ki-67 variable had a clear causal relationship to cancer cell proliferation for all cell lines except MDA-MB-231. The Ki-67 count increased as cells prepared to divide, and with the generalized uncontrolled growth exhibited by cancer cells, a large Ki-67 count indicates significant cancer growth [17]. Thus, tumor suppression goes hand-in-hand with a decrease in Ki-67 due to its vital role in the continuance of the cell cycle itself [17,29]. The reason MDA-MB-231 did not display Ki-67 causality with cell proliferation may be due to the cell line’s inherent level of resistance to CAP and its low levels of Ki-67 already present within the cells [2,5]. MDA-MB-231’s receptor status may also account for why the majority of its variables, including cell cycle activity in the G1 phase, showed no significant causality [5].
When analyzing the general outputs of the causality function, it was seen that all variables displayed a Granger causal relationship with cell proliferation only after CAP treatment for 5 min. This may suggest that CHCP directly initiates and executes apoptotic cell death and reduces cell proliferation in a more pronounced way the longer the cells are treated with the cold plasma. With longer treatment times, oxidative responses and caspase-dependent events may increasingly influence the cleavage of specific substrates to propagate the proapoptotic signal, directly influencing cancer cell proliferation [16]. Out of the significant cell proliferation models, it can be seen that most of the coefficients of regression for each cell line were greater for the 5 min treatment time than the coefficient for the 3 min treatment time. This increase suggests that CAP effectively increases its influence on cell proliferation inhibition as the cells are treated for longer periods of time. However, CA demonstrated a decrease in its causal effect for each cell line as treatment time increased. While causality is still observed, other variables must be considered. A longer treatment time may enact other factors to play a larger role in reducing cell proliferation.
For the cell death models, it was seen that the 3 min MDA-MB-231 model detected no causality for any variable. This, again, may be due to the highly aggressive nature of the cell line as it lacks functional ER, PR, and HER2 expression. However, after being treated with CAP for 5 min, ROS and Ki-67 showed causality. G1 remained insignificant. G1 activity is a typical indicator of cell growth that is required for DNA synthesis and mitosis, and therefore low G1 activity may elicit apoptosis and cell cycle arrest if regulatory checks are not met within the cell cycle [18]. Yet, both the cell proliferation model for the 3 min treatment and the cell death model for both the 3 and 5 min treatments showed no G1 phase causality for the MDA-MB-231 cell line. This may suggest that this specific cancer type bypasses the regulatory checkpoints that are responsible to cease abnormal cell proliferation, spurring on uncontrolled cancer cell growth.
It is important to note that although Granger causality was not detected for certain relationships, this does not insinuate that one variable has absolutely no influence on another. While the Granger causality formulation may not have picked up on any causal links, there are many other variables and cellular intermediaries sparked by CAP that play a role, no matter how indirect, in controlling cancer cell growth and cell death.
While the four cell lines examined in this study, BT-474, MCF-7, MDA-MB-231, and SK-BR-3, are all invasive ductal/breast carcinoma cells, they have several phenotypic and genotypic differences that make them metabolically unique [1]. The clinical heterogeneity of the cell lines thus stems from their differences in sensitivity and responsiveness to different treatments. Different treatment modalities may be implemented into these models for future studies.


Many limitations stemmed from the lack of data availability. Had daily raw data been available for different cancer cell types, the models would have more successfully captured the complexities of CAP treatment for varying cancer stages, morphologies, and chemical intricacies. Increased cell-type diversity would have provided a more comprehensive view of the subtleties each cancer type has in terms of cell cycle arrest and programmed cell death. In addition, a consistently maintained data set on an hourly time-scale for each variable would prevent the need for any interpolation and data estimating.
Even though statistical p-values were used to detect causality, the definition of significance is subjective based on our critical value of 0.05. There is also a chance of type-1 error in which the statistical test concludes causality when in actuality there is not any, and therefore further research should be conducted to verify our findings. It may also be beneficial to incorporate high-pass/low-pass filtering of the data, which would remove any outliers present in the data.
As for model validation, heteroscedasticity tends to produce p-values that are smaller than they should be. This effect occurs because heteroscedasticity increases the variance of the coefficient estimates, but the OLS procedure does not detect this increase. Consequently, OLS calculates the t-values and F-values using an underestimated amount of variance. These values are statistical measures, which determine if there is a significant difference between the two groups of data. This problem can lead one to conclude that a model term is statistically significant when it is actually not significant.
In addition, error may in part be due to the fact that the raw data were originally collected from different cell passages, meaning one experiment was conducted prior to passaging or splitting the cells, while another may have been conducted after. The test results may also be impacted by the data cleaning processes and interpolation that were conducted prior to input into the model functions.

5. Conclusions

Our results demonstrate that Granger causality was present among all independent causal variables (ROS, caspase, Ki-67, and G1 activity) and cell proliferation after 5 min CHCP treatment. However, not all variables were causal for the 3 min models. This same pattern did not exist for cell death models, which tested all potentially causal variables (ROS, Ki-67, and G1 activity) vs. caspase activity. The receptor status for each cell line studied greatly impacted the causal influence each variable had on cell proliferation and cell death.
While the literature-based correlations among CAP, cell cycle arrest and cell death have been hypothesized, little computational modeling has been used to test such theories. Computational modeling aids in understanding the systematic series of microcellular operations that occur with cancer treatment without the need for clinical randomized controlled trials or costly research methods. The models thus serve to incentivize more research in terms of what clinical adaptations should be taken to reduce the extent of cancer’s burden on human health.
CHCP has demonstrated its ability to induce cellular oxidative stress, and the media containing CHCP-generated species are more than the mere combination of hydrogen peroxide and nitrite chemical solutions. Quantifying CHCP’s relationship to intracellular reactive oxygen species, caspase, Ki-67 expression, and cell cycle activity in the G1 phase elucidates the impact cold plasma has on disturbing different malignant cellular processes. By harnessing CAP’s innate ability to elicit certain chemical reactions in order to cease uncontrolled tumor formation, CAP has great potential as a fourth arm for cancer treatment in addition to surgery, chemotherapy, and radiation therapy.

Author Contributions

Conceptualization, A.E., X.C., S.R.K.M., T.Z., L.L., O.J. and J.C.; Data curation, A.E. and X.C.; Formal analysis, A.E. and X.C.; Investigation, A.E. and X.C.; Methodology, A.E. and X.C.; Software, A.E. and X.C.; Supervision, X.C. and J.C.; Writing—original draft, A.E. and X.C.; Writing—review and editing, A.E., X.C., S.R.K.M., T.Z., L.L., O.J., G.B., M.K. and J.C. All authors have read and agreed to the published version of the manuscript.


This research received no external funding.

Data Availability Statement

The analyzed data and data sets generated are available upon request.


The authors would like to thank the engineering team at Plasma Medicine Life Sciences for technical support of the plasma unit.

Conflicts of Interest

The authors declare no conflict of interest.


  1. Mohammed, A.A. The clinical behavior of different molecular subtypes of breast cancer. Cancer Treat. Res. Commun. 2021, 29, 100469. [Google Scholar] [CrossRef] [PubMed]
  2. Pellegrino, B.; Hlavata, Z.; Migali, C.; De Silva, P.; Aiello, M.; Willard-Gallo, K.; Musolino, A.; Solinas, C. Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Mol. Diagn. Ther. 2021, 25, 409–424. [Google Scholar] [CrossRef] [PubMed]
  3. Yamamoto, S.; Ibusuki, M.; Yamamoto, Y.; Fu, P.; Fujiwara, S.; Murakami, K.; Iwase, H. Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens. Breast Cancer 2013, 20, 262–270. [Google Scholar] [CrossRef] [PubMed]
  4. Schlam, I.; Swain, S.M. HER2-positive breast cancer and tyrosine kinase inhibitors: The time is now. NPJ Breast Cancer 2021, 7, 56. [Google Scholar] [CrossRef] [PubMed]
  5. Bianchini, G.; De Angelis, C.; Licata, L.; Gianni, L. Treatment landscape of triple-negative breast cancer—Expanded options, evolving needs. Nat. Rev. Clin. Oncol. 2021, 19, 91–113. [Google Scholar] [CrossRef]
  6. Tate, S.; Nishikimi, K.; Kato, K.; Matsuoka, A.; Kambe, M.; Kiyokawa, T.; Shozu, M. Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer. J. Gynecol. Oncol. 2020, 31, e34. [Google Scholar] [CrossRef] [Green Version]
  7. Yarana, C.; St Clair, D.K. Chemotherapy-Induced Tissue Injury: An Insight into the Role of Extracellular Vesicles-Mediated Oxidative Stress Responses. Antioxidants 2017, 6, 75. [Google Scholar] [CrossRef]
  8. Ferreira, A.R.; Di Meglio, A.; Pistilli, B.; Gbenou, A.S.; El-Mouhebb, M.; Dauchy, S.; Charles, C.; Joly, F.; Everhard, S.; Lambertini, M.; et al. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: A prospective patient-reported outcomes analysis. Ann. Oncol. 2019, 30, 1784–1795. [Google Scholar] [CrossRef]
  9. Alkabban, F.M.; Ferguson, T. Breast Cancer; StatPearls Publishing LLC: Treasure Island, FL, USA, 2022. [Google Scholar]
  10. Privat-Maldonado, A.; Bogaerts, A. Plasma in Cancer Treatment. Cancers 2020, 12, 2617. [Google Scholar] [CrossRef]
  11. Tornin, J.; Labay, C.; Tampieri, F.; Ginebra, M.P.; Canal, C. Evaluation of the effects of cold atmospheric plasma and plasma-treated liquids in cancer cell cultures. Nat. Protoc. 2021, 16, 2826–2850. [Google Scholar] [CrossRef]
  12. Ionin, A.A.; Napartovich, A.P.; Yuryshev, N.N. Physics and engineering of singlet delta oxygen production in low-temperature plasma. J. Phys. D Appl. Phys. 2007, 40, R25–R61. [Google Scholar] [CrossRef]
  13. Graves, D.B. The emerging role of reactive oxygen and nitrogen species in redox biology and some implications for plasma applications to medicine and biology. J. Phys. D Appl. Phys. 2012, 45, 263001. [Google Scholar] [CrossRef]
  14. Cheng, X.; Murthy, S.R.K.; Zhuang, T.; Ly, L.; Jones, O.; Basadonna, G.; Keidar, M.; Kanaan, Y.; Canady, J. Canady Helios Cold Plasma Induces Breast Cancer Cell Death by Oxidation of Histone mRNA. Int. J. Mol. Sci. 2021, 22, 9578. [Google Scholar] [CrossRef] [PubMed]
  15. Bauer, G.; Sersenová, D.; Graves, D.B. Cold Atmospheric Plasma and Plasma-Activated Medium Trigger RONS-Based Tumor Cell Apoptosis. Sci. Rep. 2019, 9, 14210. [Google Scholar] [CrossRef]
  16. McIlwain, D.R.; Berger, T.; Mak, T.W. Caspase functions in cell death and disease. Cold Spring Harb. Perspect. Biol. 2013, 5, a008656. [Google Scholar] [CrossRef]
  17. Li, L.T.; Jiang, G.; Chen, Q.; Zheng, J.N. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol. Med. Rep. 2015, 11, 1566–1572. [Google Scholar] [CrossRef] [Green Version]
  18. Hua, D.; Cai, D.; Ning, M.; Yu, L.; Zhang, Z.; Han, P.; Dai, X. Cold atmospheric plasma selectively induces G0/G1 cell cycle arrest and apoptosis in AR-independent prostate cancer cells. J. Cancer 2021, 12, 5977–5986. [Google Scholar] [CrossRef]
  19. Mercadante, A.K. Anup Genetics, Cancer Cell Cycle Phases; StatPearls Publishing: Treasure Island, FL, USA, 2021. [Google Scholar]
  20. Granger, C.W.J. Investigating causal relations by econometric models and cross-spectral methods. Econometrica 1969, 37, 424–438. [Google Scholar] [CrossRef]
  21. Siggiridou, E.; Koutlis, C.; Tsimpiris, A.; Kugiumtzis, D. Evaluation of Granger Causality Measures for Constructing Networks from Multivariate Time Series. Entropy 2019, 21, 1080. [Google Scholar] [CrossRef] [Green Version]
  22. Canady, J.; Shashurin, A.; Keidar, M.; Zhuang, T. Integrated Cold Plasma and High Frequency Plasma Electrosurgical System and Method. U.S. Patent 9,999,462, 19 June 2018. [Google Scholar]
  23. Rowe, W.; Cheng, X.; Ly, L.; Zhuang, T.; Basadonna, G.; Trink, B.; Keidar, M.; Canady, J. The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner. Plasma 2018, 1, 177–188. [Google Scholar] [CrossRef] [Green Version]
  24. Ly, L.; Cheng, X.; Murthy, S.R.; Zhuang, T.; Jones, O.Z.; Basadonna, G.; Keidar, M.; Canady, J. Canady cold plasma conversion system treatment: An effective inhibitor of cell viability in breast cancer molecular subtypes. Clin. Plasma Med. 2020, 19, 100109. [Google Scholar] [CrossRef]
  25. Cheng, X.; Rowe, W.; Ly, L.; Shashurin, A.; Zhuang, T.; Wigh, S.; Basadonna, G.; Trink, B.; Keidar, M.; Canady, J. Treatment of Triple-Negative Breast Cancer Cells with the Canady Cold Plasma Conversion System: Preliminary Results. Plasma 2018, 1, 218–228. [Google Scholar] [CrossRef] [Green Version]
  26. Chvosteková, M.; Jakubík, J.; Krakovská, A. Granger Causality on forward and Reversed Time Series. Entropy 2021, 23, 409. [Google Scholar] [CrossRef] [PubMed]
  27. Lim, C.; Sen, P.K.; Peddada, S.D. Accounting for Uncertainty in Heteroscedasticity in Nonlinear Regression. J. Stat. Plan. Inference 2012, 142, 1047–1062. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Brown, R.L.; Evans, J.M. Techniques for testing constancy of regression relationships over time. J. R. Stat. Soc. 1975, 37, 149–163. [Google Scholar] [CrossRef]
  29. Kanyılmaz, G.; Yavuz, B.B.; Aktan, M.; Karaağaç, M.; Uyar, M.; Fındık, S. Prognostic Importance of Ki-67 in Breast Cancer and Its Relationship with Other Prognostic Factors. Eur. J. Breast Health 2019, 15, 256–261. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Intracellular ROS measurements of breast cancer cell lines at 0–48 h post CHCP treatment. H2O2 and/or NO2 were used as positive controls. All cells were treated by CHCP at 120 p for 3 and 5 min. (A,B) Treated MCF-7 cells. (C,D) Treated BT-474 cells. (E,F) Treated MDA-MB-231 cells. (G,H) Treated SK-BR-3 cells.
Figure 1. Intracellular ROS measurements of breast cancer cell lines at 0–48 h post CHCP treatment. H2O2 and/or NO2 were used as positive controls. All cells were treated by CHCP at 120 p for 3 and 5 min. (A,B) Treated MCF-7 cells. (C,D) Treated BT-474 cells. (E,F) Treated MDA-MB-231 cells. (G,H) Treated SK-BR-3 cells.
Applsci 12 04622 g001
Figure 2. Plot of the Stability Test Output. Example plot showing the stability test outcome for the 3 min MDA-MB-231 Ki-67 model. CUSUM processes were calculated to detect structural changes in the inputted data.
Figure 2. Plot of the Stability Test Output. Example plot showing the stability test outcome for the 3 min MDA-MB-231 Ki-67 model. CUSUM processes were calculated to detect structural changes in the inputted data.
Applsci 12 04622 g002
Table 1. Classification of Breast Cancer Cell Lines and Their Characteristics. Four different breast cancers and their categorization based on receptor type are listed.
Table 1. Classification of Breast Cancer Cell Lines and Their Characteristics. Four different breast cancers and their categorization based on receptor type are listed.
ClassificationImmunoprofileKi-67 LevelExample Cell Line Used in This Study
Luminal AER+, PR+/−, HER2LowMCF-7
Luminal BER+, PR+/−, HER2+HighBT-474
Triple-negativeER, PR, HER2LowMDA-MB-231
Table 2. p-values and coefficients of linear regression for all cell proliferation models for cells treated for 3 min (* p < 0.05).
Table 2. p-values and coefficients of linear regression for all cell proliferation models for cells treated for 3 min (* p < 0.05).
Cell LineResultCause:
Cause: CaspaseCause:
BT-474p-value1.22 × 10−6 *0.095630.02058 *0.0003267 *
Coefficient of Regression0.00294920.075290.036420.006221
MCF-7p-value0.23150.000879 *<2.2 × 10−16 *1.38 × 10−13 *
Coefficient of Regression0.006152.311851.236870.047372
MDA-MB-231p-value0.13056.271 × 10−8 *0.21520.5003
Coefficient of Regression0.00058640.205760.094130.002546
SK-BR-3p-value0.0006389 *8.94 × 10−10 *0.01111 *-
Coefficient of Regression3.18 × 10−40.046260.06148-
Table 3. p-values and coefficients of linear regression for all cell proliferation models for cells treated for 5 min (* p < 0.05).
Table 3. p-values and coefficients of linear regression for all cell proliferation models for cells treated for 5 min (* p < 0.05).
Cell LineResultCause:
Cause: CaspaseCause:
BT-474p-value1.81 × 10−9 *1.08 × 10−10 *0.006065 *0.001206 *
Coefficient of Regression0.00085790.0213730.070690.012123
MCF-7p-value0.0161 *4.201 × 10−7 *0.008426 *1.19 × 10−12 *
Coefficient of Regression0.00124490.107470.062380.028388
MDA-MB-231p-value4.50 × 10−6 *1.161 × 10−8 *<2.2 × 10−16 *<2.2 × 10−16 *
Coefficient of Regression0.00070240.088490.692440.022176
SK-BR-3p-value0.04855 *3.34 × 10−12 *1.81 × 10−8 *-
Coefficient of Regression8.28 × 10−50.0511280.08787-
Table 4. p-values and coefficients of linear regression for all cell death models for cells treated for 3 min (* p < 0.05).
Table 4. p-values and coefficients of linear regression for all cell death models for cells treated for 3 min (* p < 0.05).
Cell LineResultCause:
BT-474p-value0.18230.08641 *0.03197 *
Coefficient of Regression0.0015650.033110.003271
MCF-7p-value0.001521 *0.0001978 *0.000331 *
Coefficient of Regression0.00127710.0173910.0018635
Coefficient of Regression0.00048470.090090.002259
SK-BR-3p-value5.16 × 10−7 *0.000365 *-
Coefficient of Regression2.48 × 10−40.25092-
Table 5. p-values and coefficients of linear regression for all cell death models for cells treated for 5 min (* p < 0.05).
Table 5. p-values and coefficients of linear regression for all cell death models for cells treated for 5 min (* p < 0.05).
Cell LineResultCause:
BT-474p-value0.01091 *4.726 × 10−7 *0.4513
Coefficient of Regression0.002230.263800.005350
MCF-7p-value0.23840.10010.01122 *
Coefficient of Regression0.00075370.063610.023061
MDA-MB-231p-value0.01123 *0.01146 *0.05247
Coefficient of Regression0.00050370.239590.009367
SK-BR-3p-value5.98 × 10−5 *0.006272 *-
Coefficient of Regression2.46 × 10−40.55293-
Table 6. Standard of error for cell proliferation models.
Table 6. Standard of error for cell proliferation models.
Cell LineStandard of Error
ROS ModelCaspase ModelKi-67 ModelG1 Model
3 min5 min3 min5 min3 min5 min3 min5 min
SK-BR-38.99 × 10−54.14 × 10−50.0067550.0063580.023710.01421--
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Elbedour, A.; Cheng, X.; Murthy, S.R.K.; Zhuang, T.; Ly, L.; Jones, O.; Basadonna, G.; Keidar, M.; Canady, J. The Granger Causal Effects of Canady Helios Cold Plasma on the Inhibition of Breast Cancer Cell Proliferation. Appl. Sci. 2022, 12, 4622.

AMA Style

Elbedour A, Cheng X, Murthy SRK, Zhuang T, Ly L, Jones O, Basadonna G, Keidar M, Canady J. The Granger Causal Effects of Canady Helios Cold Plasma on the Inhibition of Breast Cancer Cell Proliferation. Applied Sciences. 2022; 12(9):4622.

Chicago/Turabian Style

Elbedour, Annisa, Xiaoqian Cheng, Saravana R. K. Murthy, Taisen Zhuang, Lawan Ly, Olivia Jones, Giacomo Basadonna, Michael Keidar, and Jerome Canady. 2022. "The Granger Causal Effects of Canady Helios Cold Plasma on the Inhibition of Breast Cancer Cell Proliferation" Applied Sciences 12, no. 9: 4622.

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop